Welcome to our dedicated page for Cstone news (Ticker: CSPHF), a resource for investors and traders seeking the latest updates and insights on Cstone stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cstone's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cstone's position in the market.
CStone (OTC:CSPHF) reported ASCO 2026 Phase I data for trispecific antibody CS2009, targeting PD-1/VEGF/CTLA-4. The drug showed dose-dependent PD effects, grade ≥3 VEGF-related TRAEs of 5.1%, and clinically meaningful responses across multiple “cold” tumors and NSCLC settings.
CStone outlined global Phase III MRCT plans in first-line and second-line NSCLC and first-line pMMR/MSS mCRC starting late 2026, highlighted ongoing partnering talks with multinational pharmas, and noted recent insider share purchases signaling management confidence and expectations for Hong Kong Stock Connect inclusion.